Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) - Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian
cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of
cannabinoids, has Signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia,
The LOI establishes a significant bi-lateral relationship granting NewCanna the right to sell and distribute certain Canntab
exclusive proprietary products, and the right to utilize Canntab's know-how and patents in the in the countries of Colombia, Chile,
Paraguay and Spain.
InvestmentPitch Media has produced a "video" which provides a brief overview of this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Canntab" in the search
box.
The two parties have a 60-day period to complete a formal agreement, which will trigger a one-time, non-refundable License Fee
of US $2-million payable to Canntab by NewCanna in consideration for the exclusive license to be granted by Canntab to NewCanna.
Canntab will in turn issue NewCanna warrants to purchase up to 500,000 shares of Canntab at a price of $1.80 for 24 months.
Under the formal agreement NewCanna will have an exclusive 5-year distribution agreement for Canntab's oral sustained release
tablet formulations and undertakes to supply Canntab up to US$10 million of NewCanna cannabis oil for which Canntab will place a
deposit of US$1 million.
NewCanna would become a key supplier of raw materials for Canntab and on a cost basis which will be very favourable in
comparison to other sources worldwide. In addition to certain performance standards, the two parties will share profits on a 50/50
basis for all products sold under the agreement.
Jeff Renwick, CEO of CannTab, stated: "We welcome this key development in our business plan and the opportunity to rapidly
expand into the many potential markets for Canntab products worldwide. The wide variety of NewCanna's cannabis strains will give us
access to a full range of Cannabinoids and terpenoids to further our development pipeline. In conjunction with, our recently
announced relationship with FSD Pharma and with our progressing work with Emblem Cannabis Corporation, I believe Canntab is poised
to be the world leader in pharmaceutical grade, standardized tablet dosage of medicinal cannabis."
NewCanna, directly and through its existing partners has access to, or control over:
- Four cultivation and extraction licenses with another four licenses under application
- More than 3,000 hectares of cannabis production
- A 32,000 square foot pharmaceutical-grade extraction facility capable of processing 5,000 tonnes of raw material per day
- Colombian oil-exportation license
- Operations within the Cannabis Free Trade Zone
- Genetic registration of more than 500 strains of cannabis and wide-ranging existing distribution.
Santiago Londono, Founder and CEO of NewCanna, added: "When carefully building a global network of cultivators and
distribution channels in today's fast-growing medicinal cannabis market it is imperative to identify the best possible pharma-grade
manufacturing partners, this is why, after rigorously evaluating many other possible alliances, we have decided Canntab has the
vision, infrastructure and knowledge that represents our best interest moving forward. Our main goal is to deliver the most
responsible and precise dosage to every patient that trusts our brands, and we believe Canntab will be instrumental in achieving
this objective."
For more information, please visit the company's website at www.canntab.ca, contact Jeffrey Renwick, CEO, at 289-301-3812, or email jeff@canntab.ca.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story
ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing
short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com
